UnknownNot Applicable

iLIVE Medication Study

Netherlands, Sweden, Switzerland400 participantsStarted 2021-01-15

Plain-language summary

The iLIVE medication study is a before-after study where medication optimisation of patients with an estimated life expectancy of six months is investigated. The investigators will include 400 patients in 3 countries. The primary outcome is an assessment of the quality of life of patients, four weeks after baseline assessment

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient is 18 years or over and provides informed consent to participate.
✓. The patient is aware that recovering from his/her disease is unlikely, as assessed by the attending physician.
✓. The patient agrees to participate in the iLIVE cohort study.
✓. The attending physician would not be surprised if the patient would die within 6 months ('Surprise question').
✓. If the physician is uncertain about the surprise question, the patient is eligible if presenting with at least one SPICT indicator. The SPICT™ is a tool to help professionals identify people with general indicators of poor or deteriorating health and clinical signs of life-limiting conditions for assessment and care planning, based on general or disease-specific indicators.

Exclusion criteria

✕. The patient is incapable of filling in a questionnaire in the country's main language or in English (patients may be supported by relatives when filling in the questionnaire).
✕. The attending physician makes the decision that the patient should not be included in the study due to e.g. illness burden, fast deterioration or imminent death, lack of trusting relationship with the physician.

What they're measuring

Patients' quality of life

Timeframe: 4 weeks after baseline assessment

Trial details

NCT IDNCT04717882

SponsorProf. dr. Stefan Sleijfer

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-15

Contact for this trial

Eline Elsten, MD

+316-51996165 e.e.c.m.elsten@erasmusmc.nl

View on ClinicalTrials.gov More Palliative Care trials